Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation
Understanding predictors of smoking cessation medication efficacy enhances the ability to improve treatment effectiveness. In our pilot trial, extended-release exenatide, a GLP-1 receptor agonist, adjunct to nicotine patch, improved smoking abstinence in smokers with prediabetes and/or overweight. The current post-hoc analysis found that the effect of exenatide on smoking abstinence may be moderated by the number of cigarettes smoked daily, metabolic, psychological, and genetic factors. Larger investigations are needed to confirm and extend these findings.
Authors
- Constanza de Dios (ORCID: https://orcid.org/0000-0003-0230-5222)
- Joy M. Schmitz (ORCID: https://orcid.org/0000-0002-3561-4614)
- David A. Nielsen (ORCID: https://orcid.org/0000-0002-2583-0233)
- Luba Yammine (ORCID: https://orcid.org/0000-0001-5639-8802)
- Consuelo Walss‐Bass (ORCID: https://orcid.org/0000-0003-2474-5448)
- Robert Suchting (ORCID: https://orcid.org/0000-0002-2822-3754)
- Charles E. Green (ORCID: https://orcid.org/0000-0001-9192-8215)
Institutions
- Baylor College of Medicine (US)
- John S. Dunn Foundation (US)
- Center for Clinical Research (United States) (US)
- The University of Texas Health Science Center (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Nicotine & Tobacco Research
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1093/ntr/ntaf005
- Citations
- 10
- Primary Topic
- Smoking Behavior and Cessation
- Type
- article
- Field-Weighted Citation Impact
- 11.64